Current Science

Open Access Open Access  Restricted Access Subscription Access

A New Magnetic Resonance Imaging Probe Specifically Targeting Vascular Endothelial Growth Factor Receptor 2:Synthesis, Characterization and Biological Evaluation


Affiliations
1 Department of Radiology, The Affiliated Hospital of Southern Medical University, Nanfang Hospital, No. 1838, Guangzhou Ave, Guangzhou, 510000, China
 

Vascular endothelial growth factor (VEGF) is strongly expressed in most tumours and promotes both tumour growth and vascularization. The peptide, VEGF125-136, consisting of 12 amino acids is encoded by exon 6 of the VEGF gene and inhibits VEGF activity by blocking the binding of VEGF to the VEGFR2 receptor. The aim of the present study was to develop a targeting probe for magnetic resonance imaging (MRI) of tumours by conjugating VEGF125-136 to gadolinium (III) (Gd(III)) (VGd) through the formation of chelates. The targeting efficiency of VGd to human hepatocellular carcinoma (HCC) cell line, BEL-7402, was subsequently determined both in vitro and in vivo. In the in vitro studies, the MRI results of BEL-7402 cells treated with VGd showed significantly higher T1 signal-to-noise ratio than that of both the competitive group, namely, those treated with VGd and VEGF125-136 and the control group, a scramble peptide conjugated to Gd(III) (SGd). In vivo, when xenografts of BEL-7402 cells were established in mice and then VGd or SGd were injected via tail vein, MRI showed that the tumour signal from VGd initially decreased from 5 to 120 min and then it increased at 120 min post injection. The peak signal was observed at 120 min after injection. In contrast, no distinct peak was observed for SGd. These findings indicate that VGd can target VEGFR2, highly expressed by BEL-7402 cells, enabling targeting MRI with high efficacy to be achieved both in vitro and in vivo.

Keywords

Gadolinium, Liver Cancer Xenograft, MRI, Peptide, VEGF125–136.
User
Notifications
Font Size

  • Li, C. et al., Gold-coated Fe3O4 nanoroses with five unique functions for cancer cell targeting, imaging and therapy. Adv. Funct. Mater., 2014, 24, 1772–1780.

  • Tan, M., Ye, Z., Lindner, D., Brady-Kalnay, S. M. and Lu, Z. R., Synthesis and evaluation of a targeted nanoglobular dual-modal imaging agent for MR imaging and image-guided surgery of prostate cancer. Pharm. Res., 2014, 31, 1469–1476.

  • Li, J. et al., A choline derivate-modified nanoprobe for glioma diagnosis using MRI. Sci. Rep., 2013, 3, 1623.

  • Kuo, T. et al., AS1411 aptamer-conjugated Gd2O3: Eu nanoparticles for target-specific computed tomography/magnetic resonance/ fluorescence molecular imaging. Nano Res., 2014, 7, 658–669.

  • Curtet, C., Maton, F., Havet, T., Slinkin, M., Mishra, A., Chatal, J. F. and Muller, R. N., Polylysine-Gd-DTPAn and polylysine-GdDOTAn coupled to anti-CEA F(ab')2 fragments as potential immunocontrast agents. Relaxometry, biodistribution, and magnetic resonance imaging in nude mice grafted with human colorectal carcinoma. Invest. Radiol., 1998, 33, 752–761.

  • Ke, T., Jeong, E. K., Wang, X., Feng, Y., Parker, D. L. and Lu, Z. R., RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta 3 integrin with MRT, mapping. Int. J. Nanomed., 2007, 2, 191–199.

  • Flacke, S. et al., Novel MRI contrast agent for molecular imaging of fibrin implications for detecting vulnerable plaques. Circulation, 2001, 104, 1280–1285.

  • Amirbekian, V. et al., Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl. Acad. Sci. USA, 2007, 104, 961–966.

  • Sieber, M. A., Pietsch, H., Walter, J., Haider, W., Frenzel, T. and Weinmann, H. J., A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadoliniumbased contrast media. Invest. Radiol., 2008, 43, 65–75.

  • Tan, M. and Lu, Z. R., Integrin targeted MR imaging. Theranostics, 2011, 1, 83–101.

  • Zhou, Z., Wu, X., Kresak, A., Griswold, M. and Lu, Z.-R., Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI. Biomaterials, 2013, 34, 7683–7693.

  • Wang, Y. et al., Bioinformatics analyses of the role of vascular endothelial growth factor in patients with non-small cell lung cancer. PLoS One, 2015, 10, e0139285.

  • Wang, S. W. et al., CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumour angiogenesis in human osteosarcoma microenvironment. Carcinogenesis, 2015, 36, 104–114.

  • Pfister, N. T. et al., Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev., 2015, 29, 1298–1315.

  • Smith, B. D. et al., Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2. Mol. Cancer Ther., 2015, 14, 1–12.

  • Bainbridge, J. W. B., Jia, H., Bagherzadeh, A., Selwood, D., Ali, R. R. and Zachary, I., A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo. Biochem. Biophys. Res. Commun., 2003, 302, 793–799.

  • Naganna, N. and Madhavan, N., Soluble non-cross-linked poly(norbornene) supports for peptide synthesis with minimal reagents. J. Org. Chem., 2014, 79, 11549–11557.

  • Baxter, D., Ullman, C. G. and Mason, J. M., Library construction, selection and modification strategies to generate therapeutic peptidebased modulators of protein-protein interactions. Future Med. Chem., 2014, 6, 2073–2092.

  • Yang, Y., Zhou, J. and Yu, K., Design, synthesis, and in vitro evaluation of a binary targeting MRI contrast agent for imaging tumour cells. Amino Acids, 2014, 46, 449–457.

  • Debergh, I. et al., Molecular imaging of tumor-associated angiogenesis using a novel magnetic resonance imaging contrast agent targeting αv, β3 integrin. Ann. Surg. Oncol., 2014, 21, 1–8.

  • Han, Z. et al., EDB Fibronectin specific peptide for prostate cancer targeting. Bioconjug. Chem., 2015, 26, 830–838.

  • Leung, K., Antivascular endothelial growth factor polylactic acidpolyethylene glycol-poly-L-Lys/gadolinium-diethylenetriamine pentaacetic acid nanoparticles. Molecular Imaging and Contrast Agent Database (MICAD) (internet). Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 5 May 2012 (updated 19 July 2012) (PubMed: 22812022).


Abstract Views: 394

PDF Views: 128




  • A New Magnetic Resonance Imaging Probe Specifically Targeting Vascular Endothelial Growth Factor Receptor 2:Synthesis, Characterization and Biological Evaluation

Abstract Views: 394  |  PDF Views: 128

Authors

Xiaoguang You
Department of Radiology, The Affiliated Hospital of Southern Medical University, Nanfang Hospital, No. 1838, Guangzhou Ave, Guangzhou, 510000, China
Yikai Xu
Department of Radiology, The Affiliated Hospital of Southern Medical University, Nanfang Hospital, No. 1838, Guangzhou Ave, Guangzhou, 510000, China

Abstract


Vascular endothelial growth factor (VEGF) is strongly expressed in most tumours and promotes both tumour growth and vascularization. The peptide, VEGF125-136, consisting of 12 amino acids is encoded by exon 6 of the VEGF gene and inhibits VEGF activity by blocking the binding of VEGF to the VEGFR2 receptor. The aim of the present study was to develop a targeting probe for magnetic resonance imaging (MRI) of tumours by conjugating VEGF125-136 to gadolinium (III) (Gd(III)) (VGd) through the formation of chelates. The targeting efficiency of VGd to human hepatocellular carcinoma (HCC) cell line, BEL-7402, was subsequently determined both in vitro and in vivo. In the in vitro studies, the MRI results of BEL-7402 cells treated with VGd showed significantly higher T1 signal-to-noise ratio than that of both the competitive group, namely, those treated with VGd and VEGF125-136 and the control group, a scramble peptide conjugated to Gd(III) (SGd). In vivo, when xenografts of BEL-7402 cells were established in mice and then VGd or SGd were injected via tail vein, MRI showed that the tumour signal from VGd initially decreased from 5 to 120 min and then it increased at 120 min post injection. The peak signal was observed at 120 min after injection. In contrast, no distinct peak was observed for SGd. These findings indicate that VGd can target VEGFR2, highly expressed by BEL-7402 cells, enabling targeting MRI with high efficacy to be achieved both in vitro and in vivo.

Keywords


Gadolinium, Liver Cancer Xenograft, MRI, Peptide, VEGF125–136.

References





DOI: https://doi.org/10.18520/cs%2Fv113%2Fi05%2F869-876